company background image
DGNS logo

Diagnos Laboratorium Utama IDX:DGNS Stock Report

Last Price

Rp228.00

Market Cap

Rp285.0b

7D

-1.7%

1Y

-15.6%

Updated

21 Nov, 2024

Data

Company Financials

PT Diagnos Laboratorium Utama Tbk

IDX:DGNS Stock Report

Market Cap: Rp285.0b

PT Diagnos Laboratorium Utama Tbk Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Diagnos Laboratorium Utama
Historical stock prices
Current Share PriceRp228.00
52 Week HighRp436.00
52 Week LowRp188.00
Beta0.44
11 Month Change-12.98%
3 Month Change-1.72%
1 Year Change-15.56%
33 Year Change-69.80%
5 Year Changen/a
Change since IPO-15.56%

Recent News & Updates

Recent updates

Shareholder Returns

DGNSID HealthcareID Market
7D-1.7%-3.1%-2.2%
1Y-15.6%19.3%9.3%

Return vs Industry: DGNS underperformed the ID Healthcare industry which returned 19.3% over the past year.

Return vs Market: DGNS underperformed the ID Market which returned 9.3% over the past year.

Price Volatility

Is DGNS's price volatile compared to industry and market?
DGNS volatility
DGNS Average Weekly Movement10.6%
Healthcare Industry Average Movement5.8%
Market Average Movement5.5%
10% most volatile stocks in ID Market12.6%
10% least volatile stocks in ID Market2.4%

Stable Share Price: DGNS's share price has been volatile over the past 3 months compared to the ID market.

Volatility Over Time: DGNS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of ID stocks.

About the Company

FoundedEmployeesCEOWebsite
200791Mesha Sinidiagnos.co.id

PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers clinical pathology laboratory tests comprising hematology, hemostasis, clinical chemistry, urinalysis, biomolecular, immunology, microbiology, and anatomical pathology; and genomics laboratory tests that provides genetic testing for reproductive health, pregnant women, couples who want to have a child, oncology tests, drug sensitivity, DNAandMe, and others. It also offers homecare health services for hemoglobin, ferritin, retilulosit, hematologi rutin, SARS-COV-2 omicron screening molecular test, and PCR SARS-COV-2 H+1 B2C; and SARS-CoV-2 screening services.

PT Diagnos Laboratorium Utama Tbk Fundamentals Summary

How do Diagnos Laboratorium Utama's earnings and revenue compare to its market cap?
DGNS fundamental statistics
Market capRp285.00b
Earnings (TTM)-Rp4.76b
Revenue (TTM)Rp155.53b

1.8x

P/S Ratio

-59.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DGNS income statement (TTM)
RevenueRp155.53b
Cost of RevenueRp88.78b
Gross ProfitRp66.75b
Other ExpensesRp71.51b
Earnings-Rp4.76b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.81
Gross Margin42.92%
Net Profit Margin-3.06%
Debt/Equity Ratio17.8%

How did DGNS perform over the long term?

See historical performance and comparison